Paras Of India Draws Acquisition Interest Of Major Drug MNCs
This article was originally published in PharmAsia News
Executive SummaryIndia's Paras Pharma, a major producer of over-the-counter drugs in the country, has drawn bids from at least four international drug makers seeking to buy the company
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.